Uppsala, Sweden, 2013-03-01 08:49 CET (GLOBE NEWSWIRE) --  

THIRD QUARTER November 1, 2012 – January 31, 2013

• Consolidated Net sales amounted to € 0 thousand (0)[1]
• Operating income amounted to € -1,670 thousand (-2,014)
• Net income after tax amounted to € -1,802 thousand (-1,999)
• Earnings per share amounted to € -0.02 (-0.03)
• Comprehensive income amounted to € -1,802 thousand (-1,999)

• Oasmia and Abbott enter into a global collaboration agreement for the veterinary oncology market
• Nexttobe increases its ownership in Oasmia
• Preferential rights new share issue completed

THE PERIOD May 1, 2012 – January 31, 2013

• Consolidated Net sales amounted to € 0 thousand (103)
• Operating income amounted to € -5,296 thousand (-5,349)
• Net income after tax amounted to € -5,733 thousand (-5,327)
• Earnings per share amounted to € -0.09 (-0.10)
• Comprehensive income amounted to € -5,733 thousand (-5,327)

EVENTS AFTER CLOSING DAY

• Oasmia and Pharmasyntez enter into a distribution agreement for Paclical® in Russia and CIS

[1] The numbers in parentheses concern results from the corresponding period of the previous year

         Johan Edin, acting Head of PR & Communications +46 18 50 54 40, press@oasmia.com, twitter.com/oasmia